Clear Within, a nutritional supplement company, has partnered with DolCas Biotech, LLC to upgrade and reformulate its vegan nutricosmetic product, Clear Within, for clear skin from the inside out. DolCas Biotech’s concentrated turmeric extract, Curcugen®, was selected as the key ingredient for the nutricosmetic.
Clear Within’s product is designed for adults of all ages who want to take care of their skin without harming animals. Each bottle contains 60 veggie capsules, with vitamins and nutrients that have been widely tested and studied to help improve skin quality. The product is sold in health shops and online.
Curcumin, the main bioactive in turmeric, is known for its antibacterial and antiseptic properties and its ability to address microbial imbalances and oxidative stress. According to Innova Market Insights, launch activity of supplements with curcumin ingredients saw a year-to-year growth of 12.6% over the last 5 years, with curcumin having a 14% share in skin health (beauty from within). Mordor Intelligence also predicts that the entire curcumin market is projected to grow by a CAGR of 12.5% through 2028.
Clear Within ultimately chose Curcugen for the reformulation of its beauty-from-within supplement for a number of pivotal reasons, including its ability to boost the bioavailability of free curcumin in their formula 39-fold. Curcugen also eliminates the need for other non-active ingredients in their formulation, freeing up space in their capsules to pack in more actives, such as detox botanical, milk thistle, and the mineral integral to skin and hormone support, zinc.
Curcugen is among the top most-concentrated, yet full-spectrum turmeric ingredients on the market and is designed for a variety of formulations – for traditional applications as well as novel foods and beverages. Curcugen is also purely plant-based, non-GMO, and free from additives, synthetic and non-turmeric bioenhancers, and soy, making it appealing to consumers with dietary sensitivities.
Author
-
Similar Posts
Pharmaceuticals Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
Pharmaceuticals Innovent Announces First Participant Dosed in a Phase I Study of IBI3002 (an anti-IL-4Rα/TSLP bispecific antibody) in Australia
Pharmaceuticals Well Begun AND Half Done! – SIRONA Randomized Trial Achieves 50% enlistment
